Results 171 to 180 of about 3,573 (200)

Long‐term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high‐frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study

Headache, 2021
Piero Barbanti, Cinzia Aurilia, Luisa Fofi   +2 more
exaly  

Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double‐blind, placebo‐controlled study

Headache, 2021
Koichi Hirata, Noboru Imai
exaly  

Real-world effectiveness and tolerability of erenumab: A retrospective cohort study

Cephalalgia, 2020
Elizabeth W Loder, Rebecca Burch, Fahs
exaly  

Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: The EMPOwER study

Cephalalgia, 2021
Shuu-Jiun Wang, Naji Riachi, Yi Jing Zhao   +2 more
exaly  

Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study

Cephalalgia, 2020
Messoud Ashina, Uwe Reuter, Stephen D Silberstein   +2 more
exaly  

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

Lancet, The, 2018
Uwe Reuter, Peter Goadsby, Michel Lantéri-Minet   +2 more
exaly  

A Controlled Trial of Erenumab for Episodic Migraine

New England Journal of Medicine, 2017
Peter Goadsby, Uwe Reuter
exaly  

Real‐World Patient Experience With Erenumab for the Preventive Treatment of Migraine

Headache, 2020
Jennifer V Robblee, Katrina L Devick, Amaal J Starling   +2 more
exaly  

Erenumab/galcanezumab

Reactions Weekly, 2022
openaire   +1 more source

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine

Cephalalgia, 2018
David W Dodick, Messoud Ashina, Michel Lantéri-Minet   +2 more
exaly